Skip to main content

Table 3 Summary of responders to immunotherapies in this study. Percentage is the number of responders out of the total number treated with that particular histologic subtype

From: Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

Sarcoma type

Best response

# responders

total

%

Alveolar soft part

Partial response

2

4

50.0%

Alveolar soft part

Stable disease

2

4

50.0%

GIST

Stable disease

3

9

33.3%

Well-diff liposarcoma

Stable disease

1

2

50.0%

De-diff liposarcoma

Stable disease

2

5

40.0%

Leiomyosarcoma

Stable disease

2

12

16.7%

Osteosarcoma

Stable disease

1

5

20.0%